Drugs / ABS-1230
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07156201 | Aug 2025 → Mar 2026 overdue | — | Actio Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07600736 | May 2026 → Jan 2027 expected | epilepsy, early-onset | Actio Biosciences, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-12-05 | Actio Biosciences, Inc. | Results Actio Biosciences Announces Preclinical Data Highlighting Ability of ABS-1230 to Potently and Selectively Inhibit KCNT1 and Significantly Reduce Seizure Activity actiobiosciences.com ↗
In our preclinical work, ABS-1230 has consistently demonstrated its ability to potently and selectively inhibit KCNT1 and pathogenic mutations leading to notable reductions in seizures in a mouse model. |
| 2025-11-24 | Actio Biosciences, Inc. | Results Actio Biosciences to Present New Preclinical Data for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy, at the American Epilepsy Society Annual Meeting actiobiosciences.com ↗
ABS-1230, a selective oral small molecule inhibitor of KCNT1 broadly inhibits pathogenic mutants and reduces seizures in a mouse model of KCNT1-related epilepsy. |
| 2025-07-30 | Actio Biosciences, Inc. | Regulatory Actio Biosciences Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy actiobiosciences.com ↗
Additionally, ABS-1230 received conditional approval from the Human Research Ethics Committee (HREC) in Australia for human clinical evaluation. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABS-1230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07156201 ↗ |
| Route | Oral | “ABS-1230 given orally” NCT07156201 ↗ |